<p>根据 ICICI Prudential Asset Management Co Ltd 最近向 SEC 提交的 13F 表格，该公司在第三季度将其在安进公司（NASDAQ:AMGN - 免费报告）的持股增加了 35.9%。该基金在此期间购买了 8,529 股后，持有 32,267 股该医疗研究公司的股票。安进约占 ICICI Prudential Asset Management Co Ltd 投资组合的 1.0%，是其第 23 大持仓。截止最近一个季度末，ICICI Prudential Asset Management Co Ltd 在安进的持股价值为 9,106,000 美元。</p>
<ul>
<li>Ozempic、Mounjaro、Wegovy 或 Zepbound？这个 ETF 包含了它们所有。</li>
</ul>
<p>其他几家机构投资者也买卖了该公司的股票。Pekin Hardy Strauss Inc.在第三季度购买了安进的新股份，价值约为 204,000 美元。Clear Creek Financial Management LLC 在第三季度将其在安进的股份增加了 19.0%。Clear Creek Financial Management LLC 现在持有 2,438 股该医疗研究公司的股票，价值 688,000 美元，此前在上个季度又购买了 390 股。BNP PARIBAS ASSET MANAGEMENT Holding S.A.在第三季度将其在安进的股份增加了 22.5%。BNP PARIBAS ASSET MANAGEMENT Holding S.A.现在持有 192,706 股该医疗研究公司的股票，价值 53,918,000 美元，此前在上个季度又购买了 35,423 股。Wealth Alliance LLC 在第三季度将其在安进的持仓增加了 4.6%。Wealth Alliance LLC 现在持有 13,412 股该医疗研究公司的股票，价值 3,785,000 美元，此前在此期间又购买了 595 股。最后，King Luther Capital Management Corp 在第三季度将其在安进的股份增加了 0.3%。King Luther Capital Management Corp 现在持有 509,158 股该医疗研究公司的股票，价值 143,684,000 美元，此前在上个季度又购买了 1,653 股。机构投资者持有该公司 76.50% 的股票。</p>
<h2>安进股价下跌 1.1%</h2>
<p>安进股票周五开盘价为 375.50 美元。安进公司 12 个月低点为 261.43 美元，12 个月高点为 385.12 美元。该公司的 50 日移动平均线为 342.07 美元，200 日移动平均线为 315.70 美元。公司的市值为 2024.2 亿美元，市盈率为 26.39，市盈增长比率为 3.89，贝塔值为 0.46。公司的债务与股本比率为 5.78，流动比率为 1.14，速动比率为 0.90。</p>
<ul>
<li>三家医疗巨头刚刚提高了股息——看看谁支付得最多</li>
</ul>
<p>安进（NASDAQ:AMGN - 获取免费报告）最近于 2 月 3 日（星期二）发布了其财报。该医疗研究公司报告本季度每股收益为 5.29 美元，超出分析师一致预期的 4.76 美元，超出幅度为 0.53 美元。该公司本季度的收入为 98.7 亿美元，而一致预期为 94.6 亿美元。安进的净利润率为 20.98%，股本回报率为 148.37%。与去年同期相比，该公司本季度的收入增长了 8.6%。在去年同期，该公司每股收益为 5.31 美元。安进已将其 2026 财年的指导目标设定为 21.600-23.000 美元每股收益。研究分析师平均预计安进公司今年将发布 20.62 美元每股收益。</p>
<h2>安进增加股息</h2>
<p>该公司最近还披露了季度股息，将于 3 月 6 日（星期五）支付。2 月 13 日（星期五）的股东将获得每股 2.52 美元的股息。这相当于每年 10.08 美元的股息，收益率为 2.7%。除息日期为 2 月 13 日（星期五）。这比安进之前的季度股息 2.38 美元有所增加。安进的股息支付比率（DPR）为 70.84%。</p>
<h2>分析师评级变动</h2>
<ul>
<li>5 家医疗公司值得关注，因为行业轮动正在全面展开</li>
</ul>
<p>几家研究公司最近对安进进行了评估。高盛集团将安进的目标价从 403.00 美元上调至 415.00 美元，并在 2 月 4 日（星期三）的报告中给予该公司 “买入” 评级。Erste Group Bank 在 12 月 5 日（星期五）的研究报告中将安进的评级从 “持有” 上调至 “买入”。Cantor Fitzgerald 将安进的目标价从 315.00 美元上调至 350.00 美元，并在 2 月 4 日（星期三）的研究报告中给予该公司 “中性” 评级。BMO 资本市场将安进的目标价从 335.00 美元上调至 372.00 美元，并在 12 月 3 日（星期三）的研究报告中给予该股票 “跑赢大盘” 评级。最后，Oppenheimer 将安进的目标价设定为 400.00 美元，并在 1 月 29 日（星期四）的报告中给予该公司 “跑赢大盘” 评级。一位研究分析师对该股票给予了强烈买入评级，十五位分析师给予了买入评级，十位分析师给予了持有评级，两位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 345.16 美元。</p>
<p><strong>获取我们关于安进的最新股票报告</strong></p>
<h2>关于安进</h2>
<p>（免费报告）</p>
<p>安进公司（NASDAQ: AMGN）是一家成立于 1980 年，总部位于加利福尼亚州千橡市的全球生物技术公司。该公司专注于发现、开发、生产和提供针对严重疾病的人类治疗药物。安进的工作集中在源自细胞和分子生物学的生物药物上，强调将人类遗传学和蛋白质科学的进展转化为患者的治疗方案。</p>
<p>安进的商业产品组合历来包括用于肿瘤学、支持性护理、肾脏病、骨骼健康和心血管疾病的生物制剂。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票比安进更好</li>
<li>3 个迹象表明您可能想更换财务顾问</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>解锁：埃隆·马斯克的下一个大 IPO</li>
<li>我的爱泼斯坦故事</li>
<li>新法律：国会批准数字美元的设立？</li>
</ul>
<p><strong>想知道其他对冲基金持有 AMGN 的情况吗？</strong> 请访问 HoldingsChannel.com 获取 Amgen Inc.（NASDAQ:AMGN - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Amgen 吗？</h2>
<p>在你考虑 Amgen 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Amgen 并不在名单上。</p>
<p>虽然 Amgen 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

医疗业 ETF - SPDR

标普全球医疗股指数 ETF - iShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>ICICI Prudential Asset Management Co Ltd 在第三季度将其在安进（Amgen Inc.）的持股增加了 35.9%，额外购买了 8,529 股，总持股达到 32,267 股，价值 910 万美元。其他机构投资者也增加了对安进的投资。该股票开盘价为 375.50 美元，12 个月的价格区间为 261.43 美元至 385.12 美元。安进最近报告了强劲的收益，超出预期，并宣布将每股股息提高至 2.52 美元，收益率为 2.7%</p>

<p>ICICI Prudential Asset Management Co Ltd increased its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 35.9% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 32,267 shares of the medical research company's stock after purchasing an additional 8,529 shares during the period. Amgen makes up about 1.0% of ICICI Prudential Asset Management Co Ltd's investment portfolio, making the stock its 23rd largest position. ICICI Prudential Asset Management Co Ltd's holdings in Amgen were worth $9,106,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根据 ICICI Prudential Asset Management Co Ltd 最近向 SEC 提交的 13F 表格，该公司在第三季度将其在安进公司（NASDAQ:AMGN - 免费报告）的持股增加了 35.9%。该基金在此期间购买了 8,529 股后，持有 32,267 股该医疗研究公司的股票。安进约占 ICICI Prudential Asset Management Co Ltd 投资组合的 1.0%，是其第 23 大持仓。截止最近一个季度末，ICICI Prudential Asset Management Co Ltd 在安进的持股价值为 9,106,000 美元。</p>
</div><ul>
<li>Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All</li>
</ul>
<div class="lb-trans"><ul>
<li>Ozempic、Mounjaro、Wegovy 或 Zepbound？这个 ETF 包含了它们所有。</li>
</ul>
</div><p>Several other institutional investors have also bought and sold shares of the business. Pekin Hardy Strauss Inc. purchased a new stake in shares of Amgen during the 3rd quarter valued at about $204,000. Clear Creek Financial Management LLC increased its stake in Amgen by 19.0% during the third quarter. Clear Creek Financial Management LLC now owns 2,438 shares of the medical research company's stock worth $688,000 after acquiring an additional 390 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in Amgen by 22.5% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 192,706 shares of the medical research company's stock worth $53,918,000 after acquiring an additional 35,423 shares during the last quarter. Wealth Alliance LLC raised its position in Amgen by 4.6% during the third quarter. Wealth Alliance LLC now owns 13,412 shares of the medical research company's stock valued at $3,785,000 after purchasing an additional 595 shares during the period. Finally, King Luther Capital Management Corp lifted its stake in shares of Amgen by 0.3% in the 3rd quarter. King Luther Capital Management Corp now owns 509,158 shares of the medical research company's stock valued at $143,684,000 after purchasing an additional 1,653 shares during the last quarter. Institutional investors own 76.50% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者也买卖了该公司的股票。Pekin Hardy Strauss Inc.在第三季度购买了安进的新股份，价值约为 204,000 美元。Clear Creek Financial Management LLC 在第三季度将其在安进的股份增加了 19.0%。Clear Creek Financial Management LLC 现在持有 2,438 股该医疗研究公司的股票，价值 688,000 美元，此前在上个季度又购买了 390 股。BNP PARIBAS ASSET MANAGEMENT Holding S.A.在第三季度将其在安进的股份增加了 22.5%。BNP PARIBAS ASSET MANAGEMENT Holding S.A.现在持有 192,706 股该医疗研究公司的股票，价值 53,918,000 美元，此前在上个季度又购买了 35,423 股。Wealth Alliance LLC 在第三季度将其在安进的持仓增加了 4.6%。Wealth Alliance LLC 现在持有 13,412 股该医疗研究公司的股票，价值 3,785,000 美元，此前在此期间又购买了 595 股。最后，King Luther Capital Management Corp 在第三季度将其在安进的股份增加了 0.3%。King Luther Capital Management Corp 现在持有 509,158 股该医疗研究公司的股票，价值 143,684,000 美元，此前在上个季度又购买了 1,653 股。机构投资者持有该公司 76.50% 的股票。</p>
</div><h2>Amgen Trading Down 1.1%</h2>
<div class="lb-trans"><h2>安进股价下跌 1.1%</h2>
</div><p>AMGN stock opened at $375.50 on Friday. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $385.12. The firm's 50-day moving average is $342.07 and its 200 day moving average is $315.70. The company has a market capitalization of $202.42 billion, a PE ratio of 26.39, a P/E/G ratio of 3.89 and a beta of 0.46. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.</p>
<div class="lb-trans"><p>安进股票周五开盘价为 375.50 美元。安进公司 12 个月低点为 261.43 美元，12 个月高点为 385.12 美元。该公司的 50 日移动平均线为 342.07 美元，200 日移动平均线为 315.70 美元。公司的市值为 2024.2 亿美元，市盈率为 26.39，市盈增长比率为 3.89，贝塔值为 0.46。公司的债务与股本比率为 5.78，流动比率为 1.14，速动比率为 0.90。</p>
</div><ul>
<li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li>
</ul>
<div class="lb-trans"><ul>
<li>三家医疗巨头刚刚提高了股息——看看谁支付得最多</li>
</ul>
</div><p>Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts' consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company's revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.</p>
<div class="lb-trans"><p>安进（NASDAQ:AMGN - 获取免费报告）最近于 2 月 3 日（星期二）发布了其财报。该医疗研究公司报告本季度每股收益为 5.29 美元，超出分析师一致预期的 4.76 美元，超出幅度为 0.53 美元。该公司本季度的收入为 98.7 亿美元，而一致预期为 94.6 亿美元。安进的净利润率为 20.98%，股本回报率为 148.37%。与去年同期相比，该公司本季度的收入增长了 8.6%。在去年同期，该公司每股收益为 5.31 美元。安进已将其 2026 财年的指导目标设定为 21.600-23.000 美元每股收益。研究分析师平均预计安进公司今年将发布 20.62 美元每股收益。</p>
</div><h2>Amgen Increases Dividend</h2>
<div class="lb-trans"><h2>安进增加股息</h2>
</div><p>The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.7%. The ex-dividend date is Friday, February 13th. This is an increase from Amgen's previous quarterly dividend of $2.38. Amgen's dividend payout ratio (DPR) is 70.84%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度股息，将于 3 月 6 日（星期五）支付。2 月 13 日（星期五）的股东将获得每股 2.52 美元的股息。这相当于每年 10.08 美元的股息，收益率为 2.7%。除息日期为 2 月 13 日（星期五）。这比安进之前的季度股息 2.38 美元有所增加。安进的股息支付比率（DPR）为 70.84%。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 家医疗公司值得关注，因为行业轮动正在全面展开</li>
</ul>
</div><p>Several research firms recently weighed in on AMGN. The Goldman Sachs Group increased their price target on Amgen from $403.00 to $415.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, February 4th. Erste Group Bank upgraded shares of Amgen from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Friday, December 5th. Cantor Fitzgerald increased their target price on shares of Amgen from $315.00 to $350.00 and gave the company a &#34;neutral&#34; rating in a research note on Wednesday, February 4th. BMO Capital Markets lifted their price target on shares of Amgen from $335.00 to $372.00 and gave the stock an &#34;outperform&#34; rating in a research note on Wednesday, December 3rd. Finally, Oppenheimer set a $400.00 price target on shares of Amgen and gave the company an &#34;outperform&#34; rating in a report on Thursday, January 29th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $345.16.</p>
<div class="lb-trans"><p>几家研究公司最近对安进进行了评估。高盛集团将安进的目标价从 403.00 美元上调至 415.00 美元，并在 2 月 4 日（星期三）的报告中给予该公司 “买入” 评级。Erste Group Bank 在 12 月 5 日（星期五）的研究报告中将安进的评级从 “持有” 上调至 “买入”。Cantor Fitzgerald 将安进的目标价从 315.00 美元上调至 350.00 美元，并在 2 月 4 日（星期三）的研究报告中给予该公司 “中性” 评级。BMO 资本市场将安进的目标价从 335.00 美元上调至 372.00 美元，并在 12 月 3 日（星期三）的研究报告中给予该股票 “跑赢大盘” 评级。最后，Oppenheimer 将安进的目标价设定为 400.00 美元，并在 1 月 29 日（星期四）的报告中给予该公司 “跑赢大盘” 评级。一位研究分析师对该股票给予了强烈买入评级，十五位分析师给予了买入评级，十位分析师给予了持有评级，两位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 345.16 美元。</p>
</div><p><strong>Get Our Latest Stock Report on Amgen</strong></p>
<div class="lb-trans"><p><strong>获取我们关于安进的最新股票报告</strong></p>
</div><h2>About Amgen</h2>
<div class="lb-trans"><h2>关于安进</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.</p>
<div class="lb-trans"><p>安进公司（NASDAQ: AMGN）是一家成立于 1980 年，总部位于加利福尼亚州千橡市的全球生物技术公司。该公司专注于发现、开发、生产和提供针对严重疾病的人类治疗药物。安进的工作集中在源自细胞和分子生物学的生物药物上，强调将人类遗传学和蛋白质科学的进展转化为患者的治疗方案。</p>
</div><p>Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.</p>
<div class="lb-trans"><p>安进的商业产品组合历来包括用于肿瘤学、支持性护理、肾脏病、骨骼健康和心血管疾病的生物制剂。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Amgen</li>
<li>3 Signs You May Want to Switch Financial Advisors</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Unlocked: Elon Musk’s Next Big IPO</li>
<li>My Epstein Story</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比安进更好</li>
<li>3 个迹象表明您可能想更换财务顾问</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>解锁：埃隆·马斯克的下一个大 IPO</li>
<li>我的爱泼斯坦故事</li>
<li>新法律：国会批准数字美元的设立？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding AMGN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对冲基金持有 AMGN 的情况吗？</strong> 请访问 HoldingsChannel.com 获取 Amgen Inc.（NASDAQ:AMGN - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AMGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Amgen Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Amgen 吗？</h2>
</div><p>Before you consider Amgen, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Amgen 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Amgen 并不在名单上。</p>
</div><p>While Amgen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Amgen 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

ICICI Prudential Asset Management Co Ltd Purchases 8,529 Shares of Amgen Inc. $AMGN

Market Beat

Affiliated Managers

动态生物技术与基因组 ETF - Invesco

安进

基因改革 ETF - ARK

Invesco Nasdaq Biotechnology ETF

2 倍做多纳斯达克生物技术 ETF - ProShares

美国制药 ETF - iShares

医药突破 ETF - ALPS

医疗业 ETF - Vanguard

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 ETF - SPDR

ICICI Prudential 资产管理有限公司购入了 8,529 股安进公司（Amgen Inc.）的股票